ALF-5755
Phase 2Small molecule
ALF-5755 is one of 13 small molecule programs targeting Acute Liver Failure. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Acute Liver Failure
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
L-Ornithine L-Aspartate
IInstitute of Liver and Biliary Sciences, India
Phase 2
Ornithine Phenylacetate
OOcera Therapeutics
Phase 2
Plasma Exchange
SanofiPreclinical
Granulocyte Colony-Stimulating Factor
SanofiPreclinical
ALF-5755
AAlfact Innovation
Phase 2
Exosome
PParacrine Therapeutics Dermatology Pte. Ltd.
Phase 1
Stemchymal
SSteminent Biotherapeutics Inc.
Phase 1
N-Acetyl-L-Cysteine
PPeking University People's Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ALF-5755. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAlfact Innovation